TY - JOUR
T1 - Smoking Cessation After Diagnosis of Kidney Cancer Is Associated With Reduced Risk of Mortality and Cancer Progression: A Prospective Cohort Study
AU - Sheikh, Mahdi
AU - Mukeriya, Anush
AU - Zahed, Hana
AU - Feng, Xiaoshuang
AU - Robbins, Hilary A.
AU - Shangina, Oxana
AU - Matveev, Vsevolod
AU - Brennan, Paul
AU - Zaridze, David
N1 - Generated from Scopus record by KAUST IRTS on 2023-09-21
PY - 2023/5/20
Y1 - 2023/5/20
N2 - PURPOSETo investigate whether postdiagnosis smoking cessation may affect the risk of death and disease progression in patients with renal cell carcinoma (RCC) who smoked at the time of diagnosis.METHODSTwo hundred twelve patients with primary RCC were recruited between 2007 and 2016 from the Urological Department in N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia. Upon enrollment, a structured questionnaire was completed, and the patients were followed annually through 2020 to repeatedly assess their smoking status and disease progression. Survival probabilities and hazards for all-cause and cancer-specific mortality and disease progression were investigated using extended the Kaplan-Meier method, time-dependent Cox proportional hazards regression, and Fine-Gray competing-risk models.RESULTSPatients were followed for a median of 8.2 years. During this time, 110 cases of disease progression, 100 total deaths, and 77 cancer-specific deaths were recorded. Eighty-four patients (40%) quit smoking after diagnosis. The total person-years at risk for this analysis were 748.2 for continuing smoking and 611.2 for quitting smoking periods. At 5 years of follow-up, both overall survival (85% v 61%) and progression-free survival (80% v 57%) rates were higher during the quitting than continuing smoking periods (both P
AB - PURPOSETo investigate whether postdiagnosis smoking cessation may affect the risk of death and disease progression in patients with renal cell carcinoma (RCC) who smoked at the time of diagnosis.METHODSTwo hundred twelve patients with primary RCC were recruited between 2007 and 2016 from the Urological Department in N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia. Upon enrollment, a structured questionnaire was completed, and the patients were followed annually through 2020 to repeatedly assess their smoking status and disease progression. Survival probabilities and hazards for all-cause and cancer-specific mortality and disease progression were investigated using extended the Kaplan-Meier method, time-dependent Cox proportional hazards regression, and Fine-Gray competing-risk models.RESULTSPatients were followed for a median of 8.2 years. During this time, 110 cases of disease progression, 100 total deaths, and 77 cancer-specific deaths were recorded. Eighty-four patients (40%) quit smoking after diagnosis. The total person-years at risk for this analysis were 748.2 for continuing smoking and 611.2 for quitting smoking periods. At 5 years of follow-up, both overall survival (85% v 61%) and progression-free survival (80% v 57%) rates were higher during the quitting than continuing smoking periods (both P
UR - https://ascopubs.org/doi/10.1200/JCO.22.02472
UR - http://www.scopus.com/inward/record.url?scp=85159727771&partnerID=8YFLogxK
U2 - 10.1200/JCO.22.02472
DO - 10.1200/JCO.22.02472
M3 - Article
C2 - 36989465
SN - 0732-183X
VL - 41
SP - 2747
EP - 2755
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 15
ER -